TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8229139

Group type: EXPERIMENTAL
Intervention: Reg A (based on the Berlin‐Frankfurt‐Münster 1976 regimen)
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Reg B (the New York regimen)
Number of subjects: 545

Group type: COMPARATOR
Intervention: Reg C (control regimen)
Number of subjects: 545
Study: 3536495

Group type: EXPERIMENTAL
Intervention: Glucose (1g/kg body weight) 45 min before exercise
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glycerol (1g/kg body weight) 45 min before exercise
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glycerol and Glucose
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: All dietary treatments
Number of subjects: 6
Study: 29883984

Group type: EXPERIMENTAL
Intervention: Wearing a white coat (WC) during postpartum rounds
Number of subjects: 178

Group type: COMPARATOR
Intervention: Not wearing a white coat (no-WC) during postpartum rounds
Number of subjects: 178
Study: 29897589

Group type: COMPARATOR
Intervention: Lubiprostone (for phenanthrene opioids)
Number of subjects: 1296

Group type: COMPARATOR
Intervention: Lubiprostone (for phenylpiperidine opioids)
Number of subjects: 1296

Group type: COMPARATOR
Intervention: Lubiprostone (for diphenylheptane opioids)
Number of subjects: 1296
Study: 26414626

Group type: EXPERIMENTAL
Intervention: Combination of oxytocin and motherwort injection
Number of subjects: 165

Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 165
Study: 24814852

Group type: EXPERIMENTAL
Intervention: Unilateral pedicle screw instrumentation
Number of subjects: 65

Group type: COMPARATOR
Intervention: Bilateral pedicle screw instrumentation
Number of subjects: 65
Study: 22926137

Group type: EXPERIMENTAL
Intervention: Normoxia (21% O2) during low-intensity exercise (40% Wmax)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hypoxia (16% O2) during low-intensity exercise (40% Wmax)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hyperoxia (100% O2) during low-intensity exercise (40% Wmax)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison of MCAv and PCAv between 40 and 80% Wmax with normoxia
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison of MCAv and PCAv at 60% Wmax with hypoxia and hyperoxia
Number of subjects: 10
Study: 20728288

Group type: EXPERIMENTAL
Intervention: Heroin (diacetylmorphine)
Number of subjects: 938

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 938

Group type: EXPERIMENTAL
Intervention: Psychoeducation (PSE)
Number of subjects: 938

Group type: COMPARATOR
Intervention: Case Management (CM)
Number of subjects: 938
Study: 17513653

Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated 1% ropivacaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1% plain ropivacaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2.5% lidocaine and 2.5% prilocaine mixture (EMLA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 20% benzocaine gel
Number of subjects: 30
Study: 16393717

Group type: EXPERIMENTAL
Intervention: Interactive educational intervention (INT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control standard asthma education (CON)
Number of subjects: 0
Study: 12564951

Group type: EXPERIMENTAL
Intervention: Low-current, long-duration iontophoresis (approximately 0.1 mA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Higher-current, shorter-duration iontophoresis (1.5-4.0 mA)
Number of subjects: 0
Study: 10357333

Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Perphenazine 70 microg/kg
Number of subjects: 100
Study: 8889352

Group type: EXPERIMENTAL
Intervention: Low goal MAP < or = 92 mm Hg
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Usual goal MAP 102-107 mm Hg
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Atenolol, Amlodipine, or Enalapril (three antihypertensive drug regimens)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Attendance at scheduled monthly follow-up visits
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Overall attendance and medication adherence
Number of subjects: 94
Study: 1984386

Group type: EXPERIMENTAL
Intervention: 40 or 80 micrograms of rgp 160
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 10 micrograms of hepatitis B vaccine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 6684932

Group type: EXPERIMENTAL
Intervention: i.v. infusion of 20 mg diltiazem in 20 min
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: peroral solution of 120 mg diltiazem
Number of subjects: 6

Group type: COMPARATOR
Intervention: two 60 mg tablets of diltiazem (Dilzem)
Number of subjects: 6
Study: 31381878

Group type: EXPERIMENTAL
Intervention: Woman's Condom (WC) in efficacy substudy
Number of subjects: 503

Group type: COMPARATOR
Intervention: Woman's Condom (WC) in functionality study
Number of subjects: 503
Study: 29681015

Group type: EXPERIMENTAL
Intervention: Cryotherapy (cooled glove/sock worn for 15 min before, during, and after paclitaxel infusion)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Cryotherapy (cooled glove/sock)
Number of subjects: 29
Study: 26103920

Group type: EXPERIMENTAL
Intervention: Familias Preparando la Nueva Generación (FPNG) + keepin'it REAL (kiR)
Number of subjects: 267

Group type: COMPARATOR
Intervention: keepin'it REAL (kiR)
Number of subjects: 267
Study: 25516315

Group type: EXPERIMENTAL
Intervention: Probiotics three times daily for 8 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 24122637

Group type: EXPERIMENTAL
Intervention: Nobori stent with biolimus A9
Number of subjects: 22
Study: 20678136

Group type: EXPERIMENTAL
Intervention: Vertical augmentation with anorganic bovine bone blocks and delayed 5-month placement of ≥10 mm implants
Number of subjects: 60

Group type: COMPARATOR
Intervention: 7-mm-long implants
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vertical augmentation with anorganic bovine bone blocks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 17953635

Group type: EXPERIMENTAL
Intervention: Etoricoxib (selective COX-2 inhibitor)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 16371185

Group type: EXPERIMENTAL
Intervention: Calcium carbonate/cholecalciferol therapy (calcium carbonate: 1500 mg per day; cholecalciferol 400 UI per day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Calcium lactogluconate/calcium carbonate (mg 300 per day)
Number of subjects: 120
Study: 12168172

Group type: EXPERIMENTAL
Intervention: Biosem plug
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Cemlock plug
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Thackray plug
Number of subjects: 93
Study: 10424696

Group type: EXPERIMENTAL
Intervention: White noise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Silence
Number of subjects: 0
Study: 8555805

Group type: EXPERIMENTAL
Intervention: Full health check (health education with feedback on cholesterol concentration and risk score)
Number of subjects: 1632

Group type: EXPERIMENTAL
Intervention: Full health check
Number of subjects: 1632
Study: 2106714

Group type: EXPERIMENTAL
Intervention: Cyclic estradiol-desogestrel therapy for 6 months
Number of subjects: 26

Group type: COMPARATOR
Intervention: Non-climacteric control group
Number of subjects: 26
Study: 7457591

Group type: EXPERIMENTAL
Intervention: Cutaneous icing
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cutaneous brushing
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo conditions
Number of subjects: 12
Study: 31268132

Group type: EXPERIMENTAL
Intervention: Tubaramure program (food-assisted multisectoral nutrition program)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tubaramure program
Number of subjects: 60
Study: 29236639

Group type: EXPERIMENTAL
Intervention: MenB‐FHbp
Number of subjects: 6896
Study: 26910781

Group type: EXPERIMENTAL
Intervention: Clindamycin-Gentamicin solution (Group 2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Physiologic saline (Group 1)
Number of subjects: 80
Study: 24690206

Group type: EXPERIMENTAL
Intervention: Women with dyspareunia
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Partners of women with dyspareunia
Number of subjects: 38
Study: 23118072

Group type: EXPERIMENTAL
Intervention: DBT/GISTM (n = 13)
Number of subjects: 36

Group type: COMPARATOR
Intervention: DBT/GISTM-S (n = 12)
Number of subjects: 36

Group type: COMPARATOR
Intervention: DBT/C (n = 11)
Number of subjects: 36
Study: 19047285

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg on days 1 and 2 with chemotherapy on day 3 (150 PRE)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Erlotinib 1,500 mg on days 1 and 2 with chemotherapy on day 3 (1,500 PRE)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Chemotherapy on day 1 with erlotinib 1,500 mg on days 2 and 3 (1,500 POST)
Number of subjects: 86
Study: 17606173

Group type: EXPERIMENTAL
Intervention: Studies with concurrent economic evaluation
Number of subjects: 12294

Group type: COMPARATOR
Intervention: Studies without concurrent economic evaluation
Number of subjects: 12294

Group type: EXPERIMENTAL
Intervention: Between group difference
Number of subjects: 12294
Study: 14687093

Group type: EXPERIMENTAL
Intervention: 12% sevoflurane
Number of subjects: 0

Group type: COMPARATOR
Intervention: 8% sevoflurane
Number of subjects: 0
Study: 11701073

Group type: EXPERIMENTAL
Intervention: Pure sesame oil
Number of subjects: 79

Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution (ISCS)
Number of subjects: 79
Study: 9073140

Group type: EXPERIMENTAL
Intervention: Intraduodenal triglyceride infusion under euglycemic conditions
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intraduodenal triglyceride infusion under hyperglycemic conditions
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison of hyperglycemia vs euglycemia during intraduodenal triglyceride infusion
Number of subjects: 10
Study: 7526027

Group type: EXPERIMENTAL
Intervention: L-asparaginase (L-ASP) added to consolidation therapy for average risk patients (MRG)
Number of subjects: 1468

Group type: EXPERIMENTAL
Intervention: G-CSF administered in intervals between intensification elements for high risk patients (HRG)
Number of subjects: 1468

Group type: EXPERIMENTAL
Intervention: Initial response to a 7-day exposure to prednisone and first intrathecal injection of MTX
Number of subjects: 1468

Group type: EXPERIMENTAL
Intervention: Presence of blasts in the bone marrow (BM) at day 15 of treatment
Number of subjects: 1468

Group type: EXPERIMENTAL
Intervention: Overall treatment protocol including 8-drug induction, consolidation, reinduction, and maintenance therapy
Number of subjects: 1468

Group type: EXPERIMENTAL
Intervention: Preventive cranial irradiation (12 Gy) for MRG and HRG patients
Number of subjects: 1468

Group type: EXPERIMENTAL
Intervention: Overall probability for event-free survival (p-EFS)
Number of subjects: 1468

Group type: EXPERIMENTAL
Intervention: Mortality rates
Number of subjects: 1468
Study: 3319643

Group type: EXPERIMENTAL
Intervention: Human insulin infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Porcine insulin infusion
Number of subjects: 10
Study: 30025308

Group type: EXPERIMENTAL
Intervention: In-home PMTO
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: In-home PMTO (completers)
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: In-home PMTO (non-completers)
Number of subjects: 918

Group type: COMPARATOR
Intervention: Services as usual (SAU)
Number of subjects: 918
Study: 27238465

Group type: EXPERIMENTAL
Intervention: Titanium-nitride-oxide-coated bioactive stents (BAS)
Number of subjects: 827

Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 827
Study: 26351359

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 1123

Group type: EXPERIMENTAL
Intervention: Plaque length
Number of subjects: 1123
Study: 23447373

Group type: EXPERIMENTAL
Intervention: Donepezil (10mg daily for 3 months)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 21306238

Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg once daily)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study: 19011227

Group type: EXPERIMENTAL
Intervention: 10-minute lymphatic treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Rest (control)
Number of subjects: 15
Study: 12824973

Group type: EXPERIMENTAL
Intervention: Oral contraceptive/clomiphene citrate
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 48
Study: 9440034

Group type: EXPERIMENTAL
Intervention: Closed kinetic chain (barbell squat)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Open kinetic chain (knee extension and hip adduction)
Number of subjects: 24
Study: 7880697

Group type: EXPERIMENTAL
Intervention: Edrophonium 250 micrograms kg‐1
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Edrophonium 500 micrograms kg‐1
Number of subjects: 54
Study: 1975324

Group type: EXPERIMENTAL
Intervention: Local instillation of hyperosmolar glucose solution
Number of subjects: 31

Group type: COMPARATOR
Intervention: Local and systemic prostaglandins
Number of subjects: 31
Study: 29812

Group type: EXPERIMENTAL
Intervention: Amiloride (5 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hydrochlorthiazide (50 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of Amiloride and Hydrochlorthiazide (50 + 5 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30679770

Group type: EXPERIMENTAL
Intervention: 1 mA anodal tDCS of right M1
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 28
Study: 28542805

Group type: EXPERIMENTAL
Intervention: Higher hydrocortisone (HCT) dose (0.4-0.6 mg/kg body weight)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Lower hydrocortisone (HCT) dose (0.2-0.3 mg/kg body weight)
Number of subjects: 47
Study: 26384721

Group type: EXPERIMENTAL
Intervention: Home visits by volunteers and community mobilisation events to promote immunisation in intervention group villages.
Number of subjects: 432

Group type: COMPARATOR
Intervention: Community mobilisation to promote nutrition in control group villages.
Number of subjects: 432
Study: 23524089

Group type: EXPERIMENTAL
Intervention: Diltiazem (0 mg, 30 mg, 60 mg, 120 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Verapamil (0 mg, 30 mg, 60 mg, 120 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg) with naloxone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Verapamil (60 mg) with naloxone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Verapamil (60 mg)
Number of subjects: 8
Study: 21271460

Group type: EXPERIMENTAL
Intervention: Education group (n=31)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (n=32)
Number of subjects: 63
Study: 19592625

Group type: EXPERIMENTAL
Intervention: Albiglutide 30 mg weekly
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Albiglutide 50 mg biweekly
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Albiglutide 100 mg monthly
Number of subjects: 356

Group type: COMPARATOR
Intervention: Exenatide (active reference)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Albiglutide (30 mg weekly, 50 mg biweekly, 100 mg monthly)
Number of subjects: 356
Study: 17010541

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 14709461

Group type: EXPERIMENTAL
Intervention: Anterior three-in-one femoral (FEM) technique
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Posterior psoas compartment (PSOAS) technique
Number of subjects: 24

Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 24
Study: 11546900

Group type: EXPERIMENTAL
Intervention: Wallenberg's syndrome (WS) patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Patients with unilateral hemispheric stroke
Number of subjects: 20

Group type: COMPARATOR
Intervention: Patients with unilateral peripheral 9th and 10th cranial nerve palsies
Number of subjects: 20
Study: 9766261

Group type: EXPERIMENTAL
Intervention: Octreotide (50 mcg) administered through continuous subcutaneous night infusion from midnight to 08:00 at increasing rate between 03:00 and 08:00 h
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Octreotide (50 mcg) administered through subcutaneous injections at 20:00, 22:00, and 24:00 h
Number of subjects: 8

Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 8
Study: 7828258

Group type: EXPERIMENTAL
Intervention: Oral ephedrine 30 mg, orally, 30 min before subarachnoid block
Number of subjects: 200

Group type: COMPARATOR
Intervention: Routine premedication only (Control Group)
Number of subjects: 200
Study: 3046593

Group type: EXPERIMENTAL
Intervention: Combined non‐specific and specific immunotherapy (BCG and neuraminidase‐treated autologous tumour cells) over a 2 year programme
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 301
Study: 31883728

Group type: EXPERIMENTAL
Intervention: Dietary salt load
Number of subjects: 8
Study: 30421667

Group type: EXPERIMENTAL
Intervention: CareSTEPS telephone-based intervention for caregivers
Number of subjects: 39
Study: 28718223

Group type: EXPERIMENTAL
Intervention: Tät® app for self-management of stress urinary incontinence
Number of subjects: 62
Study: 26525620

Group type: EXPERIMENTAL
Intervention: naltrexone 50 mg/day + guanfacine 1 mg/day (N+G)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: naltrexone 50 mg/day + guanfacine placebo (N+GP)
Number of subjects: 301

Group type: COMPARATOR
Intervention: naltrexone placebo + guanfacine (NP+G)
Number of subjects: 301

Group type: COMPARATOR
Intervention: double placebo (NP+GP)
Number of subjects: 301
Study: 23619317

Group type: EXPERIMENTAL
Intervention: Bariatric surgery at the Bariatric and Metabolic Institute Abu Dhabi
Number of subjects: 275

Group type: COMPARATOR
Intervention: ACS NSQIP hospitals
Number of subjects: 275
Study: 22036127

Group type: EXPERIMENTAL
Intervention: Group 1 (α' < 39.5°)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Group 2 (α' ≥ 39.5°)
Number of subjects: 362
Study: 19132200

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 1935

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 1935

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1935

Group type: EXPERIMENTAL
Intervention: Heparin prophylaxis prior to enrollment
Number of subjects: 1935
Study: 17357764

Group type: EXPERIMENTAL
Intervention: Active acclimation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Passive acclimation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unacclimatized group (U)
Number of subjects: 40
Study: 15159320

Group type: EXPERIMENTAL
Intervention: 300 mg/day UDCA for 21 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 600 mg/day UDCA for 21 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 900 mg/day UDCA for 21 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: UDCA treatment
Number of subjects: 18
Study: 11328958

Group type: EXPERIMENTAL
Intervention: Preterm infant formula (discharge to 6 mo corrected age)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Term formula (discharge to 6 mo)
Number of subjects: 100
Study: 9572636

Group type: EXPERIMENTAL
Intervention: Salmon calcitonin (100 IU s.c.)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Isotonic saline (1 cc s.c.)
Number of subjects: 11
Study: 8147095

Group type: EXPERIMENTAL
Intervention: Purified hemagglutinin antigen (HA) 7.5 micrograms/0.25 ml
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Purified hemagglutinin antigen (HA) 22.5 micrograms/0.25 ml
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Purified hemagglutinin antigen (HA) 67.5 micrograms/0.25 ml
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard split product vaccine (ST) 22.5 micrograms/ml
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Purified hemagglutinin antigen (HA) highest dose
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: All vaccine groups
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Equivalent dose of HA vaccine
Number of subjects: 43
Study: 3048914

Group type: EXPERIMENTAL
Intervention: Naftifine cream 1 percent
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 60
Study: 31343950

Group type: EXPERIMENTAL
Intervention: 1:1, 45 minute, in-person intervention focused on transfers skills and seated postural control
Number of subjects: 18
Study: 29329957

Group type: EXPERIMENTAL
Intervention: SAB-301 (1 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg, 50 mg/kg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: SAB-301 (50 mg/kg)
Number of subjects: 38
Study: 28498195

Group type: EXPERIMENTAL
Intervention: INSPIRE implementation research activities
Number of subjects: 3400
Study: 26149465

Group type: EXPERIMENTAL
Intervention: EA 40,000 U subcutaneously once weekly
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: EA 80,000 U every 3 weeks
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: EA 120,000 U every 3 weeks
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: DA 500 mcg every 3 weeks
Number of subjects: 239

Group type: COMPARATOR
Intervention: All treatment arms
Number of subjects: 239
Study: 23880655

Group type: EXPERIMENTAL
Intervention: Sugar-free Red Bull (SF-RB) containing caffeine (160 mg) and taurine (2000 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Caffeine only drink (160 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sugar-free caffeine-free placebo (PL)
Number of subjects: 17
Study: 20608874

Group type: EXPERIMENTAL
Intervention: HIV-1 gp120 vaccine
Number of subjects: 0
Study: 18534501

Group type: EXPERIMENTAL
Intervention: Mini-incision surgery (MIS) group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (skin blood flow over the anterior superior iliac spine)
Number of subjects: 20
Study: 16467544

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus cetuximab
Number of subjects: 424

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 424
Study: 12780402

Group type: EXPERIMENTAL
Intervention: Timolol maleate/latanoprost fixed combination (TLFC) given once each evening
Number of subjects: 32

Group type: COMPARATOR
Intervention: Brimonidine and timolol solution given twice daily
Number of subjects: 32